Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Mécanismes des avantages de l'inhibition de l'IL4RA dans les maladies respiratoires exacerbées par l'aspirine (MARINER)

21 octobre 2026 mis à jour par: Tanya Laidlaw, MD, Brigham and Women's Hospital

Mécanismes des avantages de l'inhibition de l'IL4RA dans les maladies respiratoires exacerbées par l'aspirine : MARINER

The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).

Aperçu de l'étude

Description détaillée

The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).

Type d'étude

Interventionnel

Inscription (Réel)

17

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Brigham and Women's Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. History of AERD, defined as meeting the diagnostic triad with:

    1. History of physician-diagnosed asthma and
    2. History of physician-diagnosed nasal polyposis and
    3. History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
  2. Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.

  3. Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.

  4. Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).

  5. Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.

  6. No current smoking (not more than one instance of smoking in the last 3 months).

  7. For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.

Key Exclusion Criteria:

  1. Use of investigational drugs within 12 weeks of Screening.
  2. Use of any biologic agent within 4 months prior to Screening.
  3. Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
  4. History of any sinonasal surgery within 4 months prior to Screening
  5. Current use of zileuton
  6. Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
  7. Pregnant, nursing, or planning to become pregnant

Note: Other inclusion and exclusion criteria apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dupilumab

Subjects will receive dupilumab (300mg every-other-week for 8 weeks).

8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.

Autres noms:
  • Seringue préremplie de dupilumab [Dupixent]

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Nasal Fluid Levels of LTE4
Délai: At Week 8 (Visit 3)

The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.

At Week 8 (Visit 3)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Nasal Fluid Levels of Albumin
Délai: At Week 8 (Visit 3)

The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.

At Week 8 (Visit 3)
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Délai: At Week 8 (Visit 3)

Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

At Week 8 (Visit 3)
Rhinoscopic Total Polyp Score (TPS)
Délai: At Week 8 (Visit 3)

The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

At Week 8 (Visit 3)
Peak Nasal Inspiratory Flow (PNIF)
Délai: At Week 8 (Visit 3)

Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

At Week 8 (Visit 3)
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Délai: At Week 8 (Visit 3)

Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

At Week 8 (Visit 3)
Lung Function - Forced Expiratory Volume 1 (FEV1)
Délai: At Week 8 (Visit 3)

Patients' lung function will be assessed at week 8 with an FEV1.

At Week 8 (Visit 3)
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Délai: At Week 8 (Visit 3)

Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

At Week 8 (Visit 3)
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Délai: At Week 8 (Visit 3)

Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.

At Week 8 (Visit 3)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Rhinoscopic Total Polyp Score (TPS)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Peak Nasal Inspiratory Flow (PNIF)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Eicosanoids
Délai: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.

weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Albumin
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Urinary Levels of Eicosanoids
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Serum Tryptase
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in IgE Levels
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Eosinophilic Cationic Protein (ECP)
Délai: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Tanya M Laidlaw, MD, Brigham and Women's Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 août 2023

Achèvement primaire (Réel)

30 avril 2026

Achèvement de l'étude (Estimé)

30 décembre 2026

Dates d'inscription aux études

Première soumission

7 octobre 2022

Première soumission répondant aux critères de contrôle qualité

7 octobre 2022

Première publication (Réel)

12 octobre 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 octobre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner